Literature DB >> 21985802

Endothelial-derived hyperpolarization factor (EDHF) contributes to PlGF-induced dilation of mesenteric resistance arteries from pregnant rats.

Maurizio Mandalà1, Natalia Gokina, Carolyn Barron, George Osol.   

Abstract

The aim of this study was to investigate the cellular mechanism involved in the potent vasodilatory action of PlGF on mesenteric resistance arteries from pregnant rats. PlGF (3 nM) induced a vasodilation of 64 ± 3.8% that was completely abolished by endothelial denudation. Significant dilation (28 ± 4.0%) remained, however, in the presence of nitric oxide synthase and cyclooxygenase inhibition, and was associated with significant reductions in vascular smooth muscle cell calcium. Absence of dilation in potassium-depolarizing solution (30 mM) confirmed its dependence on endothelial-derived hyperpolarization factor. Subsequent studies established that vasodilation was abolished by pharmacologic inhibition of SK(Ca) (apamin) and BK(Ca) (iberiotoxin) but not IK(Ca) (tram-34) potassium channels. In summary, PlGF acts through the release of a combination of endothelium-derived relaxation factors. Based on the results of potassium channel blockade, we suggest that it induces endothelial hyperpolarization via SK(Ca) channel activation; this, in turn, leads to the release of a diffusible mediator that activates vascular smooth muscle BK(Ca) channels, hyperpolarization and vasodilation. This is the first study to identify the mechanism for PlGF/VEGFR-1 resistance artery dilation in the pregnant state, whose attenuation likely contributes to the systemic hypertension characteristic of pre- eclampsia.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985802      PMCID: PMC3221268          DOI: 10.1159/000329821

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  41 in total

Review 1.  EDHF: bringing the concepts together.

Authors:  Rudi Busse; Gillian Edwards; Michel Félétou; Ingrid Fleming; Paul M Vanhoutte; Arthur H Weston
Journal:  Trends Pharmacol Sci       Date:  2002-08       Impact factor: 14.819

2.  Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice.

Authors:  Ashley K Woods; Darren S Hoffmann; Christine J Weydert; Scott D Butler; Yi Zhou; Ram V Sharma; Robin L Davisson
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

3.  Differential effects of ascorbate on endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation in the bovine ciliary vascular bed and coronary artery.

Authors:  Alister J McNeish; Silvia Nelli; William S Wilson; Fiona J Dowell; William Martin
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor.

Authors:  Shaun L Sandow; Marianne Tare; Harold A Coleman; Caryl E Hill; Helena C Parkington
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

5.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.

Authors:  Hikaru Sugimoto; Yuki Hamano; David Charytan; Dominic Cosgrove; Mark Kieran; Akulapalli Sudhakar; Raghu Kalluri
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

7.  Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia.

Authors:  Louise C Kenny; Philip N Baker; David A Kendall; Michael D Randall; William R Dunn
Journal:  Clin Sci (Lond)       Date:  2002-07       Impact factor: 6.124

8.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

Review 9.  Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?

Authors:  Rosana D Meyer; Nader Rahimi
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

10.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.

Authors:  Monica Autiero; Johannes Waltenberger; Didier Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul Van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

View more
  16 in total

1.  Hemodynamic, vascular, and reproductive impact of FMS-like tyrosine kinase 1 (FLT1) blockade on the uteroplacental circulation during normal mouse pregnancy.

Authors:  Eliyahu V Khankin; Maurizio Mandala; Ilsley Colton; S Ananth Karumanchi; George Osol
Journal:  Biol Reprod       Date:  2012-02-29       Impact factor: 4.285

Review 2.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

Review 3.  Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia.

Authors:  Frank T Spradley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-30       Impact factor: 3.619

Review 4.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

5.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14

Review 6.  Uteroplacental circulation and fetal vascular function and development.

Authors:  Kent L Thornburg; Samantha Louey
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

7.  The SK3 channel promotes placental vascularization by enhancing secretion of angiogenic factors.

Authors:  Cara C Rada; Grace Murray; Sarah K England
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-23       Impact factor: 4.310

8.  Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles.

Authors:  Xinguo Jiang; Andrey V Malkovskiy; Wen Tian; Yon K Sung; Wenchao Sun; Joe L Hsu; Sathish Manickam; Dhananjay Wagh; Lydia-Marie Joubert; Gregg L Semenza; Jayakumar Rajadas; Mark R Nicolls
Journal:  Biomaterials       Date:  2013-10-22       Impact factor: 12.479

9.  Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy.

Authors:  Minglin Zhu; Zongli Ren; José S Possomato-Vieira; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-06-08       Impact factor: 3.619

10.  Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Wentao Yu; Wei Gao; Dan Rong; Zhixian Wu; Raouf A Khalil
Journal:  Microcirculation       Date:  2018-10-19       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.